



April 1st 2021

HYAMEDIX ApS RECEIVES FUNDING TO ACCELERATE GROWTH OF KEY PIPELINE PROJECTS.

Hyamedix ApS announced today that it successfully raised 1 million EURO in order to accelerate its 3 key pipeline projects: [Senso™](#), [DX1™](#) and [Gelferon™](#)

The new funds were raised with the help from [Greystone Capital Partners A/S](#) and Marigold Innovation ApS, and form a syndication of Jesper Ahlmann Funding Andersen, Anders K. Bønding, and [Marigold Innovation ApS](#) with a loan from [Vækstfonden](#).

Jesper Ahlmann Funding Andersen

Private Investor and current Board member in Hyamedix

“I am delighted for the opportunity to support Hyamedix on its exciting growth journey – both with capital and in my role as new board member. The company does in my view possess a technology for controlled release of pharmaceutical ingredients that have wide applicability across therapeutic areas. The commercial prospects are enticing”

Todd Kenworth

Founder, CEO & Chairman of the Board, Hyamedix ApS

“In order to accelerate our current growth, we’ve chosen to work with several key investors in the Danish market to help fund our current pipeline and to accelerate time to market for our 3 key pipeline projects. This includes the production of clinical material to be used in all three clinical trials”

Peter Horn Møller, PhD

CEO, Partner, Marigold Innovations ApS

“It has been a pleasure for us to be able to create the optimal team together with Hyamedix and build Hyamedix’ investment case. Together and with our individual competencies I believe that we once again have shown the strength of teamwork to secure Hyamedix’s further development. On top of this, we are happy to have been given the opportunity to continue as team members and join the syndicate”

About Hyamedix ApS

Hyamedix is a **drug development** company specialized in **improving drug delivery and drug release profiles in order to improve their safety and efficacy** with the use of a **naturally occurring molecule** of the human body, **Hyaluronan (HA)**, a well-known, **safe, biodegradable and biocompatible** molecule. Based on this we develop bespoke drug products combining customized hydrogel formulations with selected APIs for novel/unmet clinical needs.



Michael Foldager
Chief Operations Officer

T: +45 53 52 00 44

W: www.hyamedix.com

E: mf@hyamedix.com